Zenas BioPharma Inc. (NASDAQ:ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).IgG4-RD is an immune system disorder where the body creates excess IgG4 antibodies, leading to inflammation and dense, tumor-like tissue growths (fibrosis) in multiple organs. Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of I ...